Association study of genetic polymorphisms in GABRD with treatment response and dose in methadone maintenance treatment

2021 ◽  
Author(s):  
Xiaohu Xie ◽  
Jun Gu ◽  
Dingding Zhuang ◽  
Xiaoyu Chen ◽  
Yun Zhou ◽  
...  
Keyword(s):  
Treatment Response ◽  
Methadone Maintenance Treatment ◽  
Maintenance Treatment ◽  
Methadone Maintenance ◽  
Methadone Treatment ◽  
Heroin Addiction ◽  
High Dose ◽  
Nucleotide Polymorphisms ◽  
Single Nucleotide ◽  
Delta Subunit

Aim: This study determined if gene variants in the GABA receptor delta subunit ( GABRD) are associated with treatment response and dose in methadone maintenance treatment (MMT) for heroin addiction. Materials & methods: A total of 286 MMT patients were recruited and divided into response and nonresponse groups based on retention time in therapy. A total of 177 responders were classified into low dose and high dose subgroups according to the stabilized methadone dose. Four (single nucleotide polymorphisms) SNPs (rs13303344, rs4481796, rs2376805 and rs2229110) in GABRD were genotyped using the TaqMan SNP assay. Logistic regression was used to assess the genetic effects of the SNPs in MMT. Results: No significant associations were observed between the SNPs and treatment response or dose, except the frequency of haplotype ACGC at the four SNPs significantly differed between responders and nonresponders. Conclusion: The results indicated that GABRD variants may play a small role in modulating methadone treatment response.

Prediction of 7 months methadone maintenance treatment response by four measures of antisociality

1998 ◽  
Vol 49 (3) ◽  
pp. 217-223 ◽  
Author(s):  
Arthur I Alterman ◽  
Megan J Rutherford ◽  
John S Cacciola ◽  
James R McKay ◽  
Chris R Boardman
Keyword(s):  
Treatment Response ◽  
Methadone Maintenance Treatment ◽  
Maintenance Treatment ◽  
Methadone Maintenance

scholarly journals ABCB1, CYP2B6, and CYP3A4 genetic polymorphisms do not affect methadone maintenance treatment in HCV-positive patients

2020 ◽  
Vol 71 (4) ◽  
pp. 353-358
Author(s):  
Davorka Sutlović ◽  
Željko Ključević ◽  
Sendi Kuret
Keyword(s):  
Hepatitis C ◽  
Genetic Polymorphisms ◽  
Methadone Maintenance Treatment ◽  
Maintenance Treatment ◽  
Methadone Maintenance ◽  
Gas Chromatography Mass Spectrometry ◽  
Major Influence ◽  
Single Nucleotide ◽  
Significant Difference ◽  
Methadone Metabolism

AbstractThe aim of this study was to determine the influence of ABCB1, CYP2B6, and CYP3A4 genetic polymorphisms on methadone metabolism in patients with hepatitis C virus (HCV) undergoing methadone maintenance treatment (MMT). The study included 35 participants undergoing MMT, who were divided in three groups: HCV-positive (N=12), HCV-negative (N=16), and HCV clinical remission (CR) (N=7). The concentrations of methadone and its main metabolite 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP) were determined with gas chromatography-mass spectrometry. The patients were genotyped for ABCB1 rs1045642, CYP2B6 rs3745274, CYP3A4 rs2242480, and CYP3A4 rs2740574 polymorphisms. Differences between single nucleotide polymorphism (SNP) genotypes and methadone-to-EDDP ratio were analysed with one-way ANOVA, which showed no significant difference between the genes (p=0.3772 for ABCB1 rs1045642, p=0.6909 for CYP2B6 rs3745274, and p=0.6533 for CYP3A4 rs2242480). None of the four analysed SNP genotypes correlated with methadone-to-EDDP concentration ratio. A major influence on it in hepatitis C-positive patients turned out to be the stage of liver damage.

Development of a Brief Treatment Instrument for Routine Clinical Use with Methadone Maintenance Treatment Clients: The Methadone Treatment Index

2008 ◽  
Vol 43 (11) ◽  
pp. 1666-1680
Author(s):  
Daryle E. Deering ◽  
J. Douglas Sellman ◽  
Simon J. Adamson ◽  
Jacqueline Horn ◽  
Christopher M. A. Frampton
Keyword(s):  
Methadone Maintenance Treatment ◽  
Maintenance Treatment ◽  
Methadone Maintenance ◽  
Methadone Treatment ◽  
Clinical Use ◽  
Brief Treatment

Predictors of Treatment Retention in Enhanced and Standard Methadone Maintenance Treatment for HIV Risk Reduction

1997 ◽  
Vol 27 (2) ◽  
pp. 203-224 ◽  
Author(s):  
Christine E. Grella ◽  
Stuart E. Wugalter ◽  
M. Douglas Anglin
Keyword(s):  
Hiv Risk ◽  
Methadone Maintenance Treatment ◽  
Maintenance Treatment ◽  
Methadone Maintenance ◽  
Methadone Treatment ◽  
Early Discharge ◽  
The Public ◽  
Methadone Maintenance Treatment Program ◽  
First 90 Days ◽  
Hiv Seropositive

Survival analysis was used to determine the predictors of discharge from a methadone maintenance treatment program for heroin addicts at high-risk for HIV infection and/or transmission. A consistent set of predictors was identified that was associated with treatment discharge at 90 days, 12 months, 18 months, and 24 months. Individuals who, at intake, were HIV seropositive, were younger, used cocaine, drank alcohol daily, and scored high on measures of depression and interpersonal problems were at a higher risk for discharge. Receipt of enhanced methadone treatment, which included case management services, group participation, psychiatric services, contingency-based reinforcers, and transportation assistance, was associated with a higher probability of retention, particularly in the first 90 days. These findings can be used to target individuals who are vulnerable to early discharge from treatment and to provide adjunctive services that may improve retention. Several of these predictors, particularly cocaine use and psychological problems, have also been associated with HIV risk among methadone clients. Increasing retention in methadone treatment will not only improve treatment efficacy but will also address the public health imperative to limit the transmission of HIV.

Sign in / Sign up

Export Citation Format

Share Document